Biological Materials Requiring IBC Review and Approval
Research involving the following materials requires IBC review and approval of a protocol application prior to conducting experiments:
- Recombinant or Synthetic Nucleic Acids
- Human, Animal or Plant Pathogens
- Human-Derived Materials
- HHS/USDA Select Agents or Biological Toxins
The IBC Charter includes additional information about the committee’s policies and procedures:
Protocols must be submitted on or before the submission deadline for the scheduled meeting. There is no expedited approval for experiments requiring review by the full committee.
The IBC meeting dates may be updated if necessary for quorum attendance.
Meeting Date | Submission Deadline |
---|---|
February 14, 2024 (Wednesday) | January 26, 2024 (Friday) |
April 10, 2024 (Wednesday) | March 20, 2024 (Wednesday) |
June 26, 2024* (Wednesday) | June 7, 2024 (Friday) |
August 14, 2024 (Wednesday) | July 26, 2024 (Friday) |
October 9, 2024 (Wednesday) | September 20, 2024 (Friday) |
December 4, 2024* (Wednesday) | November 15, 2024 (Friday) |
- Location: Virtual Meeting via Microsoft Teams
- * In-person meetings. Location: Benson 303 (Conference Room)
- Start Time: 3 p.m.
- The laboratory must have submitted a corrective action plan for all deficiencies identified during their most recent lab safety inspection
- All personnel included on the protocol must be up-to-date on required Biosafety Training
- Any biosafety cabinet used for the project must have an updated annual certification
- All personnel included on the protocol must have completed any required occupational health services
NIH OSP Institutional Biosafety Committee Registration Management System
FAQs: NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acids [pdf]
FAQs: IBC Meetings and Minutes
FAQs: Major Actions Under Section III-A of the NIH Guidelines
Biosafety Guidance for COVID-19 Research
If you will be conducting COVID-19 research, please review the following guidance resources. You may contact Sherika Smith or Mark Robbins if you have any questions.
- CDC Information for Laboratories
- CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with COVID-19
- WHO Lab Biosafety Guidance Related to COVID-19
- Canada Biosafety Advisory- SARS-CoV-2
- Labconco Biosafety Recommendations for SARS-CoV-2 and COVID-19
- ABSA Considerations for Handling Potential SARS-CoV-2 Samples
- ABSA SARS-CoV-2 Sample Type Risk Assessment
- NIH Laboratory Biosafety Guidance for Research with SARS-CoV-2 and IBC Requirements under the NIH Guidelines
Note: To ship any COVID-19 research samples, you must have current shipping training. For questions regarding shipping training, email Sherika Smith.
- Saf-T-Pak Packaging Checklist
- IATA Packing Instructions 650 for UN 3373
- Label for UN3373: Cold pack
- Label for UN3373: Dry ice
- CDC schematic for packaging UN3373 Category B
- Pipeline and Hazardous Materials Safety Admin., DOT Materials of Trade Exceptions
- IATA: Novel Coronavirus (COVID-19): Guidance for Operators
- ABSA SARS-CoV-2 Packaging and Shipping Information